NYSE:EBS - Emergent BioSolutions Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $113.67
  • Forecasted Upside: 67.48 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$67.87
▼ -9.77 (-12.58%)
1 month | 3 months | 12 months
Get New Emergent BioSolutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EBS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EBS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$113.67
▲ +67.48% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Emergent BioSolutions in the last 3 months. The average price target is $113.67, with a high forecast of $150.00 and a low forecast of $90.00. The average price target represents a 67.48% upside from the last price of $67.87.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Emergent BioSolutions. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2021GuggenheimLower Price TargetBuy$130.00 ➝ $110.00Medium
i
4/13/2021BenchmarkInitiated CoverageBuy$150.00N/A
i
4/7/2021BenchmarkInitiated CoverageBuy$150.00Low
i
3/2/2021Chardan CapitalUpgradeNeutral ➝ Buy$112.00Medium
i
Rating by K. Nakae at Chardan Capital
2/24/2021Chardan CapitalUpgradeNeutral ➝ Buy$112.00Low
i
Rating by K. Nakae at Chardan Capital
2/19/2021Chardan CapitalDowngradeBuy ➝ Neutral$112.00High
i
Rating by K. Nakae at Chardan Capital
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$110.00High
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
i
7/31/2020Chardan CapitalBoost Price TargetBuy$86.00 ➝ $112.00High
i
Rating by Keay Nakae at Chardan Capital
7/17/2020Cantor FitzgeraldBoost Price TargetOverweight$85.00 ➝ $110.00High
i
7/2/2020Wells Fargo & CompanyBoost Price TargetOverweight$85.00 ➝ $93.00Medium
i
6/8/2020Chardan CapitalReiterated RatingBuy$86.00Low
i
Rating by Keay Nakae at Chardan Capital
6/8/2020Cantor FitzgeraldLower Price TargetOverweight$86.00 ➝ $85.00High
i
6/8/2020GuggenheimLower Price TargetBuy$101.00 ➝ $87.00High
i
6/2/2020GuggenheimBoost Price Target$81.00 ➝ $101.00Low
i
6/1/2020Chardan CapitalReiterated RatingBuy$86.00High
i
Rating by Keay Nakae at Chardan Capital
5/6/2020ArgusBoost Price TargetBuy$67.00 ➝ $90.00Low
i
5/1/2020Cantor FitzgeraldBoost Price TargetOverweight$75.00 ➝ $86.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
5/1/2020Chardan CapitalBoost Price TargetBuy$71.00 ➝ $86.00High
i
Rating by Keay Nakae at Chardan Capital
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$75.00 ➝ $85.00Low
i
4/24/2020Chardan CapitalReiterated RatingBuy$71.00High
i
Rating by Keay Nakae at Chardan Capital
3/12/2020CowenInitiated CoverageHold$67.00Medium
i
Rating by Boris Peaker at Cowen Inc
3/1/2020CowenReiterated RatingHold$67.00Low
i
2/25/2020Wells Fargo & CompanyBoost Price TargetOverweight$66.00 ➝ $75.00Medium
i
Rating by David Maris at Wells Fargo & Company
11/25/2019CowenReiterated RatingHold$67.00High
i
11/22/2019Cantor FitzgeraldReiterated RatingOverweight$75.00High
i
11/7/2019Wells Fargo & CompanyReiterated RatingBuyMedium
i
Rating by David Maris at Wells Fargo & Company
11/7/2019Chardan CapitalReiterated RatingBuy$71.00High
i
Rating by Keay Nakae at Chardan Capital
11/7/2019CowenReiterated RatingHold$67.00High
i
9/12/2019GuggenheimInitiated CoverageBuy$65.00Low
i
9/4/2019LaidlawSet Price TargetBuy$72.00Low
i
Rating by Francois Brisebois at Laidlaw
9/4/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$61.00 ➝ $64.00High
i
Rating by David Maris at Wells Fargo & Company
9/3/2019Chardan CapitalSet Price TargetBuy$71.00Low
i
Rating by Keay Nakae at Chardan Capital
7/31/2019CowenReiterated RatingHold$60.00High
i
5/10/2019Wells Fargo & CompanyLower Price TargetMarket Perform$61.00Medium
i
Rating by David Maris at Wells Fargo & Company
5/3/2019CowenReiterated RatingHold$60.00High
i
5/2/2019Cantor FitzgeraldReiterated RatingBuy$75.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
4/21/2019Cantor FitzgeraldReiterated RatingBuy$75.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
4/2/2019Wells Fargo & CompanySet Price TargetHold$68.00Low
i
Rating by David Maris at Wells Fargo & Company
3/1/2019Wells Fargo & CompanySet Price TargetHold$68.00High
i
Rating by David Maris at Wells Fargo & Company
2/22/2019Chardan CapitalSet Price TargetBuy$71.00High
i
Rating by Keay Nakae at Chardan Capital
1/25/2019Cantor FitzgeraldSet Price TargetBuy$75.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
1/4/2019Cantor FitzgeraldSet Price TargetBuy$75.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
12/13/2018Cantor FitzgeraldSet Price TargetBuy$75.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
12/12/2018Wells Fargo & CompanySet Price TargetHold$65.00High
i
Rating by David Maris at Wells Fargo & Company
11/20/2018CowenReiterated RatingHold$64.00Low
i
11/9/2018ArgusSet Price TargetBuy$80.00Low
i
Rating by Jasper Hellweg at Argus
11/2/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $75.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
11/2/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$60.00 ➝ $75.00High
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
9/11/2018Cantor FitzgeraldSet Price TargetBuy$68.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/11/2018ArgusBoost Price TargetBuy ➝ Average$70.00Low
i
Rating by Michael Jaffe at Argus
9/4/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $66.00Medium
i
8/29/2018CowenReiterated RatingHold$49.00Low
i
8/29/2018Wells Fargo & CompanySet Price TargetMarket Perform ➝ Hold$61.00 ➝ $65.00High
i
Rating by David Maris at Wells Fargo & Company
8/28/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/10/2018Wells Fargo & CompanySet Price TargetHold$61.00N/A
i
Rating by David Maris at Wells Fargo & Company
8/9/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/3/2018Chardan CapitalBoost Price TargetBuy$53.00 ➝ $57.00High
i
8/2/2018Cantor FitzgeraldReiterated RatingBuy$62.00High
i
Rating by B. Folkes at Cantor Fitzgerald
6/14/2018Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by B. Folkes at Cantor Fitzgerald
6/13/2018ArgusInitiated CoverageBuy$62.00High
i
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$62.00Medium
i
4/25/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market PerformHigh
i
Rating by David Maris at Wells Fargo & Company
4/24/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$56.00High
i
2/27/2018Singular ResearchBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00Medium
i
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$55.00Low
i
1/16/2018Chardan CapitalBoost Price TargetBuy$47.00 ➝ $53.00Medium
i
9/30/2017Wells Fargo & CompanyReiterated RatingOutperform$41.00 ➝ $43.00Medium
i
1/30/2017Chardan CapitalReiterated RatingBuy$47.00N/A
i
Rating by Keay Nakae at Chardan Capital
1/9/2017CowenReiterated RatingHoldN/A
i
12/10/2016Chardan CapitalSet Price TargetBuy$47.00N/A
i
Rating by Keay Nakae at Chardan Capital
11/9/2016Chardan CapitalReiterated RatingBuy$47.00N/A
i
10/1/2016Wells Fargo & CompanySet Price TargetBuy$41.00N/A
i
Rating by David Maris at Wells Fargo & Company
9/30/2016Wells Fargo & CompanyReiterated RatingPositive$41.00N/A
i
Rating by David Maris at Wells Fargo & Company
8/7/2016CowenReiterated RatingHold$33.00N/A
i
Rating by Eric Schmidt at Cowen Inc
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$45.00 ➝ $36.00N/A
i
6/28/2016Singular ResearchLower Price TargetBuy$44.00 ➝ $40.00N/A
i
6/22/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by David Maris at Wells Fargo & Company
6/22/2016CowenDowngradeOutperform ➝ Market PerformN/A
i
Rating by Eric Schmidt at Cowen Inc
5/2/2016Chardan CapitalReiterated RatingBuyN/A
i
Rating by Keay Nakae at Chardan Capital
(Data available from 4/19/2016 forward)
Emergent BioSolutions logo
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $67.87
$67.53
$75.24

50 Day Range

MA: $88.23
$72.76
$102.20

52 Week Range

Now: $67.87
$66.01
$137.61

Volume

1,601,242 shs

Average Volume

705,243 shs

Market Capitalization

$3.64 billion

P/E Ratio

21.82

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Emergent BioSolutions?

The following equities research analysts have issued research reports on Emergent BioSolutions in the last year: Argus, Benchmark Co., Cantor Fitzgerald, Chardan Capital, Guggenheim, JPMorgan Chase & Co., Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for EBS.

What is the current price target for Emergent BioSolutions?

6 Wall Street analysts have set twelve-month price targets for Emergent BioSolutions in the last year. Their average twelve-month price target is $113.67, suggesting a possible upside of 46.4%. Benchmark Co. has the highest price target set, predicting EBS will reach $150.00 in the next twelve months. Argus has the lowest price target set, forecasting a price of $90.00 for Emergent BioSolutions in the next year.
View the latest price targets for EBS.

What is the current consensus analyst rating for Emergent BioSolutions?

Emergent BioSolutions currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EBS will outperform the market and that investors should add to their positions of Emergent BioSolutions.
View the latest ratings for EBS.

What other companies compete with Emergent BioSolutions?

How do I contact Emergent BioSolutions' investor relations team?

Emergent BioSolutions' physical mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company's listed phone number is 240-631-3200 and its investor relations email address is [email protected] The official website for Emergent BioSolutions is www.emergentbiosolutions.com.